Nanotechnology Now – Press Release: Arrowhead Presents New Clinical Data on Cardiometabolic Pipeline at AHA 2020


Home > Press > Arrowhead Presents New Clinical Data on Cardiometabolic Pipeline at AHA 2020

Abstract:
– ARO-APOC3 achieved triglyceride reductions of 74-92%

– ARO-ANG3 achieved triglyceride reductions of 29-75% and LCL-C reductions of 29-35%

– Company to host upcoming KOL webinars on ARO-APOC3 and ARO-ANG3

Arrowhead Presents New Clinical Data on Cardiometabolic Pipeline at AHA 2020


Pasadena. CA | Posted on November 13th, 2020

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced positive clinical data from multiple product candidates in its cardiometabolic pipeline at the American Heart Association (AHA) Scientific Sessions 2020.

Javier San Martin, M.D., chief medical officer at Arrowhead, said: “The data presented at AHA on our cardiometabolic pipeline continue to show strong and consistent response across a range of lipid parameters. There remains significant residual cardiovascular risk despite recent scientific advances, and we believe that our cardiometabolic pipeline has the ability to target new therapeutic targets and address multiple lipid parameters associated with increased cardiovascular risk.”

Copies of the following presentations may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website:

Title: Pharmacodynamic effect of ARO-ANG3, an investigational RNA interference therapeutic targeting hepatic angiopoietin-like protein 3, in patients with hypercholesterolemia
Authors: Gerald F. Watts, et al.
Session: Advances in Understanding and Treatment of Dyslipidemia and New Therapies for CVD

Title: Pharmacodynamic effect of ARO-APOC3, an investigational hepatocyte-targeted RNA interference therapeutic targeting apolipoprotein C3, in patients with hypertriglyceridemia and multifactorial chylomicronemia
Authors: Christie Ballantyne, presenting on behalf of Peter Clifton, et al.
Session: Advances in Understanding and Treatment of Dyslipidemia and New Therapies for CVD

Title: Safety, Tolerability and Efficacy of Single-Dose AMG 890, a Novel siRNA Targeting Lp(a), in Healthy Subjects and Subjects with Elevated Lp(a)
Authors: Michael J. Koren, et al.
Session: Advances in Understanding and Treatment of Dyslipidemia and New Therapies for CVD

Arrowhead will also host two key opinion leader (KOL) webinars on November 18, and November 19, 2020 to discuss data from, and the company’s future plans for, its two investigational cardiometabolic candidates, ARO-APOC3 and ARO-ANG3. The webinars may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.

####

About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company’s email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts .

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

For more information, please click here

Contacts:
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400

Investors:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578

www.lifesciadvisors.com

Media:
LifeSci Communications, LLC
Josephine Belluardo, Ph.D.
646-751-4361

www.lifescicommunications.com

Copyright © Arrowhead Pharmaceuticals, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious
Digg
Newsvine
Google
Yahoo
Reddit
Magnoliacom
Furl
Facebook

News and information

SPACEX CREW-1 FLIGHT TO IMPROVE BENEFITS FROM INTERNATIONAL SPACE STATION: National Space Society’s Ongoing Support for Commercial Spaceflight Shows Results November 19th, 2020

180 Degree Capital Corp. Reports +7.4% Growth and $2.90 Per Share NAV as of September 30, 2020, and Developments From Q4 2020 November 19th, 2020

New technology allows more precise view of the smallest nanoparticles: Imaging technology offers advantages for diagnostics, other uses November 17th, 2020

NIST sensor experts invent supercool mini thermometer November 17th, 2020

Nanomedicine

Arrowhead Interim Clinical Data Demonstrate ARO-AAT Treatment Improved Multiple Biomarkers of Alpha-1 Liver Disease November 13th, 2020

Making 3-D Nanosuperconductors with DNA: Complex 3-D nanoscale architectures based on DNA self-assembly can conduct electricity without resistance and may provide a platform for fabricating quantum computing and sensing devices November 10th, 2020

‘Electronic skin’ promises cheap and recyclable alternative to wearable devices November 10th, 2020

Jet-printing microfluidic devices on demand November 6th, 2020

Announcements

SPACEX CREW-1 FLIGHT TO IMPROVE BENEFITS FROM INTERNATIONAL SPACE STATION: National Space Society’s Ongoing Support for Commercial Spaceflight Shows Results November 19th, 2020

180 Degree Capital Corp. Reports +7.4% Growth and $2.90 Per Share NAV as of September 30, 2020, and Developments From Q4 2020 November 19th, 2020

New technology allows more precise view of the smallest nanoparticles: Imaging technology offers advantages for diagnostics, other uses November 17th, 2020

NIST sensor experts invent supercool mini thermometer November 17th, 2020

Events/Classes

CEA-Leti to Present Latest Results & Insights on 3D Technologies, Power Electronics & Quantum Computing: Institute’s Experts to Host Online Tutorial on Qubit Figures of Merit And Short Course on 3D Sequential Integration November 9th, 2020

Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinars on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 November 6th, 2020

Arrowhead Pharmaceuticals to Webcast Fiscal 2020 Year End Results November 3rd, 2020

GLOBALFOUNDRIES Global Technology Conference 2020 China to Spotlight Innovations Accelerating the Digital Future: An engaging virtual event of insightful discussions and networking opportunities with thought leaders on future innovations November 2nd, 2020

Nanobiotechnology

Arrowhead Interim Clinical Data Demonstrate ARO-AAT Treatment Improved Multiple Biomarkers of Alpha-1 Liver Disease November 13th, 2020

Making 3-D Nanosuperconductors with DNA: Complex 3-D nanoscale architectures based on DNA self-assembly can conduct electricity without resistance and may provide a platform for fabricating quantum computing and sensing devices November 10th, 2020

Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinars on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 November 6th, 2020

Jet-printing microfluidic devices on demand November 6th, 2020

Leave a Reply

Your email address will not be published. Required fields are marked *